Skip to main content

Ionis Pharmaceuticals

Ionis Pharmaceuticals Inc is an American biotechnology company pioneering antisense technology for ribonucleic acid targeted drug discovery. The company discovers, develops, and commercializes RNA-targeted therapeutics designed to treat severe cardiovascular, neurological, and rare genetic diseases. Its proprietary platform enables the generation of antisense oligonucleotides that selectively regulate disease-causing protein synthesis. Revenue is derived from commercial sales of therapies like Spinraza and Wainua, milestone payments, and research royalties under partnerships with major pharmaceutical firms. Ionis holds a commanding position in genetic and RNA-targeted drug innovation globally, maintaining a deep pipeline of clinical-stage candidates. The company is headquartered in Carlsbad, California, United States, and its common stock is traded on the Nasdaq Global Select Market.

13 of the funds FundTelligence covers report a position in Ionis Pharmaceuticals.

Legal name
Ionis Pharmaceuticals Inc
Sector
Health Care
Country
United States
Funds holding it
13
Exposure themes
Genetic Medicine, Precision Medicine & Genomics, RNA Therapeutics

Funds holding Ionis Pharmaceuticals

Showing the 8 largest of 13 funds holding it.

Loading...